Camptodactyly-fibrous tissue hyperplasia-skeletal anomalies syndrome (CFTHS) is a rare genetic disorder characterized by camptodactyly (permanent flexion of the fingers), fibrous tissue hyperplasia (abnormal growth of fibrous tissue), and skeletal anomalies (abnormalities of the bones). It is caused by a mutation in the gene encoding the protein filamin A. Symptoms may include joint stiffness, joint pain, and limited range of motion. Treatment typically involves physical therapy, splinting, and medications to reduce inflammation.

The symptoms of Camptodactyly-fibrous tissue hyperplasia-skeletal anomalies syndrome (CFTS) include:

-Camptodactyly (permanent flexion of the fingers and toes)
-Fibrous tissue hyperplasia (thickening of the skin and underlying tissue)
-Skeletal anomalies (abnormal bone development)
-Joint contractures (limited range of motion in the joints)
-Short stature
-Scoliosis (curvature of the spine)
-Kyphosis (abnormal curvature of the upper spine)
-Craniosynostosis (premature fusion of the skull bones)
-Facial dysmorphism (abnormal facial features)
-Hearing loss
-Developmental delay
-Intellectual disability
-

The exact cause of Camptodactyly-fibrous tissue hyperplasia-skeletal anomalies syndrome is unknown. It is believed to be caused by a genetic mutation, but the exact gene responsible has not yet been identified. It is also possible that environmental factors may play a role in the development of this condition.

1. Physical therapy: Physical therapy can help improve range of motion and strength in affected joints.

2. Surgery: Surgery may be recommended to correct any skeletal anomalies or to release tight tendons or ligaments.

3. Splinting: Splinting can help to reduce pain and improve range of motion.

4. Occupational therapy: Occupational therapy can help with activities of daily living and help to improve fine motor skills.

5. Orthotics: Orthotics can help to support weakened joints and reduce pain.

6. Medications: Non-steroidal anti-inflammatory drugs (NSAIDs) may be prescribed to reduce pain and inflammation.

1. Genetic predisposition: Camptodactyly-fibrous tissue hyperplasia-skeletal anomalies syndrome is an inherited disorder caused by a mutation in the gene that codes for the protein filamin A.

2. Age: The syndrome is more common in children and adolescents.

3. Gender: Camptodactyly-fibrous tissue hyperplasia-skeletal anomalies syndrome is more common in males than females.

4. Family history: Individuals with a family history of the disorder are at an increased risk of developing the syndrome.

Unfortunately, there is no known cure for Camptodactyly-fibrous tissue hyperplasia-skeletal anomalies syndrome. Treatment typically focuses on managing the symptoms and complications associated with the condition. This may include physical therapy, occupational therapy, splinting, and medications to reduce pain and inflammation. Surgery may also be recommended in some cases to correct skeletal deformities.